Work

Nanoparticles and radiotracers: advances toward radionanomedicine

Year: 2016

Type: article

Abstract: In this study, we cover the convergence of radiochemistry for imaging and therapy with advances in nanoparticle (NP) design for biomedical applications. We first explore NP properties relevant for therapy and theranostics and emphasize the need for biocompatibility. We then explore radionuclide‐imaging modalities such as positron emission tomography (PET), single‐photon emission computed tomography (SPECT), and Cerenkov luminescence (CL) with examples utilizing radiolabeled NP for imaging. PET and SPECT have served as diagnostic workhorses in the clinic, while preclinical NP design examples of multimodal imaging with radiotracers show promise in imaging and therapy. CL expands the types of radionuclides beyond PET and SPECT tracers to include high‐energy electrons (β−) for imaging purposes. These advances in radionanomedicine will be discussed, showing the potential for radiolabeled NPs as theranostic agents. WIREs Nanomed Nanobiotechnol 2016, 8:872–890. doi: 10.1002/wnan.1402 This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

Source: Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology

DOI: 10.1002/wnan.1402

Authors: Edwin C. Pratt, Travis M. Shaffer, Jan Grimm

Institutions: Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, City University of New York, Hunter College

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green